dc.contributor.author | Craddock, Vaughn D. | |
dc.contributor.author | Steere, Evan L. | |
dc.contributor.author | Harman, Hannah | |
dc.contributor.author | Britt, Nicholas S. | |
dc.date.accessioned | 2023-07-11T14:29:19Z | |
dc.date.available | 2023-07-11T14:29:19Z | |
dc.date.issued | 2023-06-20 | |
dc.identifier.citation | Craddock, V.D.; Steere, E.L.; Harman, H.; Britt, N.S. Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model. Antibiotics 2023, 12, 1078. https://doi.org/10.3390/antibiotics12061078 | en_US |
dc.identifier.uri | https://hdl.handle.net/1808/34580 | |
dc.description.abstract | Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant Pseudomonas aeruginosa (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (p = 0.033) and Cmin (p = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (p = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF. | en_US |
dc.publisher | MDPI | en_US |
dc.rights | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Delafloxacin | en_US |
dc.subject | Pseudomonas aeruginosa | en_US |
dc.subject | Multidrug-resistance | en_US |
dc.subject | Carbapenem-resistance | en_US |
dc.subject | Carbapenem-resistant Pseudomonas aeruginosa | en_US |
dc.subject | Cystic fibrosis | en_US |
dc.subject | Fluoroquinolones | en_US |
dc.title | Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Craddock, Vaughn D. | |
kusw.kuauthor | Steere, Evan L. | |
kusw.kuauthor | Harman, Hannah | |
kusw.kuauthor | Britt, Nicholas S. | |
kusw.kudepartment | Pharmacy | en_US |
dc.identifier.doi | 10.3390/antibiotics12061078 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC10295321 | en_US |
dc.rights.accessrights | openAccess | en_US |